$6.24
3.85% day before yesterday
Nasdaq, Sep 06, 10:17 pm CET
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Relay Therapeutics Inc Stock price

$6.24
-0.95 13.21% 1M
-4.08 39.53% 6M
-4.77 43.32% YTD
-3.90 38.46% 1Y
-25.26 80.19% 3Y
-28.81 82.20% 5Y
-28.81 82.20% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.25 3.85%
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Key metrics

Market capitalization $835.47m
Enterprise Value $198.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.63
P/S ratio (TTM) P/S ratio 23.73
P/B ratio (TTM) P/B ratio 1.22
Revenue growth (TTM) Revenue growth 3,637.69%
Revenue (TTM) Revenue $35.21m
EBIT (operating result TTM) EBIT $-373.37m
Free Cash Flow (TTM) Free Cash Flow $-283.24m
Cash position $688.42m
EPS (TTM) EPS $-2.52
P/E forward negative
P/S forward 82.11
EV/Sales forward 19.47
Short interest 8.66%
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Relay Therapeutics Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
100%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
35 35
3,646% 3,646%
100%
- Direct Costs 5.50 5.50
16% 16%
16%
30 30
884% 884%
84%
- Selling and Administrative Expenses 64 64
2% 2%
182%
- Research and Development Expense 333 333
9% 9%
947%
-368 -368
1% 1%
-1,045%
- Depreciation and Amortization 5.50 5.50
16% 16%
16%
EBIT (Operating Income) EBIT -373 -373
1% 1%
-1,060%
Net Profit -323 -323
6% 6%
-917%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
GlobeNewsWire
one day ago
Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday, September 9, at 8am ET CAMBRIDGE, Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by co...
Neutral
GlobeNewsWire
about one month ago
Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration with Pfizer for combination development of RLY-2608 + fulvestrant + atirmociclib (CDK4i) in PI3Kα-mutated HR+/HER2- metastatic breast cancer, with clinical start planned by end of 2...
Neutral
GlobeNewsWire
3 months ago
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass.
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 323
Founded 2015
Website www.relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today